Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance…

Overview of attention for article published in Arthritis Research & Therapy, May 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

So far, Altmetric has seen 3 news stories from 3 outlets.

medwireNews: Analysis of data from 21 randomized controlled trials indicates that the interleukin-17A inhibitor secukinumab has…

15-05-2019 | Rheumatology | News | Article medwireNews: Analysis of data from 21 randomized controlled trials indicates that…

Long-term follow-up has demonstrated a favorable safety profile for secukinumab (Cosentyx) in the treatment of psoriasis (PsO)…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.